0001104659-21-031001.txt : 20210303 0001104659-21-031001.hdr.sgml : 20210303 20210302213722 ACCESSION NUMBER: 0001104659-21-031001 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210302 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0403 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 21706978 BUSINESS ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 8-K 1 tm218226d2_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2021

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Commission File Number: 001-14041

Massachusetts		04-2882273
(State or other jurisdiction of incorporation)		(IRS Employer Identification No.)

125 Summer Street Boston, MA 02110
(Address of principal executive offices, including zip code)

781-848-7100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $.01 par value per share		HAE		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

On March 2, 2021, Haemonetics Corporation issued a press release announcing that it had priced an offering of $435 million aggregate principal amount of convertible senior notes due 2026 in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Press release of Haemonetics Corporation dated March 2, 2021

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HAEMONETICS CORPORATION

Date: March 2, 2021	By:	/s/ Christopher A. Simon
	Name:	Christopher A. Simon
	Title:	President and Chief Executive Officer

EX-99.1 2 tm218226d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Haemonetics Prices $435.0 Million Convertible Senior Notes Offering

BOSTON, March 2, 2021—Haemonetics Corporation (“Haemonetics”) (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2026 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $425,000,000 aggregate principal amount of notes. The offering is expected to close on March 5, 2021, subject to customary closing conditions. Haemonetics also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $65,000,000 principal amount of notes.

The notes will be senior, unsecured obligations of Haemonetics. The notes will not bear regular interest, and the principal amount of the notes will not accrete. The notes will mature on March 1, 2026, unless earlier repurchased, redeemed or converted. Before September 1, 2025, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after September 1, 2025, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Haemonetics will settle any conversion amounts of the notes up to the $1,000 principal amount of the notes in cash, and any conversion amounts in excess of the principal amount in cash, shares of Haemonetics’ common stock or a combination thereof, at Haemonetics’ election. The initial conversion rate is 5.7033 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $175.34 per share of common stock. The initial conversion price represents a premium of approximately 40% over the last reported sale of $125.24 per share of Haemonetics’ common stock on March 2, 2021. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will not be redeemable at Haemonetics’ election before March 5, 2024. The notes will be redeemable, in whole or in part, for cash at Haemonetics’ option at any time on or after March 5, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Haemonetics’ common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date.

If a “fundamental change” (as defined in the indenture for the notes) occurs, then noteholders may require Haemonetics to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the applicable repurchase date.

Haemonetics estimates the net proceeds from the offering will be approximately $423.3 million (or approximately $486.7 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses. Haemonetics intends to use approximately $41.2 million of the net proceeds to fund the cost of entering into the capped call transactions described below and intends to use the remainder of the net proceeds from the offering to reduce the amount of indebtedness pursuant to Haemonetics’ existing credit facility, working capital and other general corporate purposes. If the initial purchasers exercise their option to purchase additional notes, then Haemonetics intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below.

- 1 -

In connection with the pricing of the notes, Haemonetics has entered into privately negotiated capped call transactions with the initial purchasers or their affiliates and other financial institutions (the “option counterparties”). The capped call transactions will cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Haemonetics’ common stock initially underlying the notes. If the initial purchasers exercise their option to purchase additional notes, Haemonetics expects to enter into additional capped call transactions with the option counterparties.

The cap price of the capped call transactions will initially be $250.48 per share, which represents a premium of approximately 100% over the last reported sale price of Haemonetics’ common stock of $125.24 per share on March 2, 2021, and is subject to certain adjustments under the terms of the capped call transactions.

The capped call transactions are expected generally to reduce or offset the potential dilution to Haemonetics’ common stock upon any conversion of the notes and/or to offset any potential cash payments Haemonetics is required to make in excess of the principal amount of the converted notes, as the case may be, upon conversion of the notes. If, however, the market price per share of Haemonetics’ common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.

Haemonetics expects that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates will enter into various derivative transactions with respect to Haemonetics’ common stock and/or purchase shares of Haemonetics’ common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Haemonetics’ common stock or the notes at that time.

In addition, Haemonetics expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Haemonetics’ common stock and/or purchasing or selling Haemonetics’ common stock or other securities of Haemonetics in secondary market transactions following the pricing of the notes and from time to time prior to the maturity of the notes (and are likely to do so following any conversion of the notes, any repurchase of the notes by Haemonetics on any fundamental change repurchase date, any redemption date or any other date on which the notes are retired by Haemonetics, in each case if Haemonetics exercises its option to terminate the relevant portion of the capped call transactions, where such termination is at the option of Haemonetics). This activity could also cause or avoid an increase or a decrease in the market price of Haemonetics’ common stock or the notes, which could affect a noteholder’s ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of the notes, it could affect the number of shares, if any, and value of the consideration that noteholders will receive upon conversion of the notes.

- 2 -

The notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and unless so registered, the notes and any such shares cannot be offered or sold except pursuant to an applicable exemption from, or in a transaction not subject to, such registration requirements. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any offer or sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

Forward-Looking Statements

This press release includes forward-looking statements, including, among other things, statements regarding the completion, timing and size of the proposed offering, and expectations regarding actions of the option counterparties and their respective affiliates. In addition, other written or oral statements that constitute forward-looking statements may be made by us or on our behalf. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “should,” “estimate,” “may,” “target,” “project,” or variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements represent the current expectations of Haemonetics regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are (i) the risk that the offering will not be consummated, (ii) changes as a result of market conditions, including market interest rates, (iii) fluctuations in the trading price and volatility of Haemonetics’ common stock, (iv) the impact of general economic, industry or political conditions in the United States or internationally, including the impact of COVID-19 and any related legislative and regulatory responses and (v) risks relating to the Haemonetics business, including those described in Haemonetics’ Annual Report on Form 10-K for the year ended March 28, 2020, filed with the Securities and Exchange Commission. The forward-looking statements included in this press release speak only as of the date of this press release, and Haemonetics does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law.

Media Contact:

Carla Burigatto, Vice President-Communications

(781) 348-7263

carla.burigatto@haemonetics.com

Investor Contact:

Olga Guyette, Director-Investor Relations

(781) 356-9763

olga.guyette@haemonetics.com

All trademarks are the property of their respective owners.

- 3 -

EX-101.SCH 3 hae-20210302.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hae-20210302_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 hae-20210302_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm218226d2_8k_htm.xml IDEA: XBRL DOCUMENT 0000313143 2021-03-02 2021-03-02 iso4217:USD shares iso4217:USD shares 0000313143 false 8-K 2021-03-02 HAEMONETICS CORPORATION 001-14041 MA 04-2882273 125 Summer Street Boston MA 02110 781 848-7100 false false false false Common Stock, $.01 par value per share HAE NYSE false XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 02, 2021
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 02, 2021
Entity File Number	001-14041
Entity Registrant Name	HAEMONETICS CORPORATION
Entity Central Index Key	0000313143
Entity Tax Identification Number	04-2882273
Entity Incorporation, State or Country Code	MA
Entity Address, Address Line One	125 Summer Street
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02110
City Area Code	781
Local Phone Number	848-7100
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $.01 par value per share
Trading Symbol	HAE
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *JL8E('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "JK&)2ZV+7&.T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OITE!(71[6?&D(+B@> O)[&ZP:4(RTN[;F\;=+J(/X#$S?[[Y M!J;306H?\3GZ@)$LIIO9#6.2.FS8D2A(@*2/Z%2J*-7?/B,0X$9#3B@PY$2\)H#ZY>) MX30/'5P!"XPPNO1=0+,22_5/;.D .R?G9-?4-$WUU)9M$(7C5MU8B=X+*]DX*_+ZX__*["SAN[M__8 M^"+8=_#K+OHO4$L#!!0 ( *JL8E*97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MJJQB4JO$Z30L! *1 !@ !X;"]W;W)K=EX48D/+O2 MJ5#PS4J;A%LX-6LO2XW@41&4Q![S_1LOX5*U^KWBVM3T>SJWL51B:DB6)PDW M;_F/=!:_?2_E:S(7]+9T:./-*E4@F0F52*V+$ZJXUH._O M6> "BCM^EV*;'1T3-Y2EUL_N9!S=M7Q')&(16B?!X>-%#$4<.R7@^&TGL1_0M=,+=9P5_\EV M=V\0M$B89U8G^V @2*3:??+7?2*. MJW)P+8/H 5W+L'%90?N.7]GM%;8MS= MH.8.BJ$6T0 GE:O*W!KX5D*<[0_UBS ]SX*4N^"%^[#[71@[$?;(S17QV05A M/J/?AGM 4&*P$H,5>FT,@_PU6&;60*'^1B3;I62[D Q.2'[080[3QY+%6RKJ M1HB'=R\_(Q!!"1&@*@,@B J*AYBOZRCP^!6/,X%P7)<^3$]!W(0149DV<7A@'R!^\A$U9/ADI1=DSET77!8N R= @.M')NR M_P0Z=&>0QH7>JEI(7.Y>0Z]3&%EE_!2W[N_)R@I/C7Z1*JS/(:Z)5[=J!Q3W M\^_1IC!J>(7_E.GI:8JCJ:E: L6]_*N1U@H%B4F27.UM+:NEPH6:^CFM M>@#%K7NN8QE**]6:/,+T-I+'M3RX2B-/9?X4]^JI$9 MNXCICSE*5)D\.\OD M1]!PURY%'T'!;IQYI%S5E_5_[@*\HXV?VT3#XAR>F)%8K$#(O^J 89O=OG1W M8G5:[ 67VL+.LCC&'<#?+_2VAY.W/:R_'6@_R]02P,$% @ JJQB M4H.II0/4 0 ,@8 T !X;"]S='EL97,N>&ULU57;BM1 $/V5IC_ GD1V M04D"*BP(*@L[#[YVDDK2T#<[E3'9K[<[G=NX#*@/HB^3.J>J3YV^3M;C).&I M T R*JG[G':(]BUC?=6!XOTK8T'[3&.5&;0F-,39476&+TSKVDD?"E70"Y.;E,;5X+8V"5VI(I/0!#M.M%WXHK$L M)!&-\D$M><GSVL(Y; RU8@Y5/8PJ_-E?;8D+@7'^NP#21,=0V]H26,,A$$ M_:-:U#[(WOV1++'B8O#]X&>C9_QM, B/#AHQSGALMOZWU)/;ZMQ:.;V3HM4* MXMQ_N6&1\74PQ6]NJ ;2\)#F-,OX7V5NP=2#D*BT OJ1%V# M?G%/O3SRTC_@5_J^OH:&#Q+/6S*G>_P9:C&H-UO58UB7I6J//X7W*+F?&^[_ M$L4/4$L#!!0 ( *JL8E*7BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://haemonetics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm218226d2_8k.htm hae-20210302.xsd hae-20210302_lab.xml hae-20210302_pre.xml tm218226d2_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm218226d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm218226d2_8k.htm" ] }, "labelLink": { "local": [ "hae-20210302_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "hae-20210302_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "hae-20210302.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "HAE", "nsuri": "http://haemonetics.com/20210302", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm218226d2_8k.htm", "contextRef": "From2021-03-02to2021-03-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://haemonetics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm218226d2_8k.htm", "contextRef": "From2021-03-02to2021-03-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://haemonetics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-031001-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-031001-xbrl.zip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end